InNexus Biotechnology, Inc.

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX: IXS.V) ( ), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today that it has engaged Dundee Securities Corporation to act as the Company’s strategic financial advisor.

BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that Jeff Morhet, Chairman and CEO, will be the keynote speaker at The Wall Street Analyst Forum, being held at the Princeton Club in New York City on Thursday, September 20, 2007. Mr. Morhet is scheduled to present at 8:30 AM ET in the amphitheater. The presentation will include an overview of the Company’s business strategy and future milestones. InNexus’ Chief Financial Officer, Wade Brooksby, will also be in attendance.

VANCOUVER, BC -- (MARKET WIRE) -- March 02, 2007 -- If you missed MN1's interview with Jeff Morhet, President, CEO & Chairman of InNexus Biotechnology, Inc. (OTCBB: IXSBF) (TSX-V: IXS), Feb. 26, 2007, at 11:00 a.m. CDT, you can still catch it by downloading the podcast on